• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Quadruple combination pill for hypertension is more effective at lowering blood pressure than standard dose monotherapy

byMinjee Kim
October 6, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Participants on reduced dose quadpill medication showed a greater reduction in blood pressure compared to participants on the standard dose irbesartan monotherapy at 12 and 52 weeks after randomization.

2. Participants on monotherapy management required more frequent uptitration compared to the quadpill group.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hypertension management is complex, often involving multiple trials of various classes of anti-hypertensives before achieving target blood pressure. It was theorized that an ultra-low-dose quadruple combination pill would be more effective as first-line treatment than standard dose monotherapy. This phase 3 Australian drug trial randomized participants with a clinical diagnosis of hypertension to receive either the quadpill of irbesartan, amlodipine, indapamide, and bisoprolol or a monotherapy control (irbesartan). Results of this study found that quadpill therapy was significantly more effective at lowering systolic and diastolic blood pressure compared to the control group. Participants on the quadpill were more likely to reach clinical blood pressure targets. There was no significant difference in adverse events between the two groups. Limitations of this study was its lower-than-target sample size due to the COVID-19 pandemic and inability to confirm patient compliance, which was only measured by pill count. Nevertheless, this phase 3 study provides promising results for the effectiveness and safety of a combination pill for hypertension.

Click to read the study in the Lancet

Relevant Reading: Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis

In-Depth [randomized controlled trial]: QUARTET is an Australian randomized, double-blinded phase 3 drug trial. There were 591 participants with either uncontrolled or monotherapy-treated hypertension. The mean age of participants was 59 years and 60% were male. 300 were randomized to the intervention group (quadpill) and 291 were randomized to monotherapy. The quadpill was a combination of 37.5 mg irbesartan, 2.5 mg bisoprolol, 1.25 mg amlodipine and 0.625 mg indapamide. The monotherapy control was 150 mg irbesartan. Office blood pressure was taken at baseline, 6 weeks, 12 weeks and 52 weeks. Analyses were done based on intention-to-treat populations.

RELATED REPORTS

Treating mild chronic hypertension associated with better pregnancy outcome

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

Intensive blood pressure control associated with increased cerebral blood flow in patients with hypertension – the SPRINT trial

At 12 weeks, the difference in systolic blood pressure between intervention and control group was -6.9 mm Hg (95% CI -4.9 to -8.9 mm Hg, p<0.001), favouring the intervention group. Diastolic blood pressure was similarly reduced in the intervention group compared to the control group by -5.8 mm Hg (p<0.0001). Secondary measures (ex. 24h systolic ambulatory blood pressure, daytime systolic BP, nighttime systolic BP) were also reduced in the intervention group compared to the control group. These differences persisted to 12 months in the participants that agreed to extended follow-up. For example, at 12 months, mean systolic office BP was -7.7 mm Hg (p<0.0001) lower in the intervention group compared to the control. In addition, for patients in the extended follow-up group, those in the monotherapy group required more frequent uptitrations compared to the quadpill intervention group (p<0.0001). As for serious adverse events, there were seven in the intervention group and three in the control group.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: #combination therapy#hypertension management#monotherapy#quartetamlodipinebisoprololblood pressureHigh Blood Pressurehypertensionindapamideirbesartanquadpillsystolic blood pressure
Previous Post

Structured aerobic exercise may produce less weight loss than expected

Next Post

#VisualAbstract: Extended letrozole therapy improves disease-free survival in postmenopausal patients with breast cancer

RelatedReports

Prenatal antidepressant exposure may increase risk of poor motor development
Cardiology

Treating mild chronic hypertension associated with better pregnancy outcome

May 13, 2022
Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Cardiology

Radiofrequency renal denervation produces long-lasting reductions in blood pressure

April 20, 2022
Parental nonmedical prescription opioid use linked to adolescent use
Cardiology

Intensive blood pressure control associated with increased cerebral blood flow in patients with hypertension – the SPRINT trial

March 8, 2022
Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Weekly Rewinds

2 Minute Medicine Rewind February 14, 2022

February 14, 2022
Next Post
#VisualAbstract: Extended letrozole therapy improves disease-free survival in postmenopausal patients with breast cancer

#VisualAbstract: Extended letrozole therapy improves disease-free survival in postmenopausal patients with breast cancer

Pediatric chronic pain patients typically Caucasian, female adolescents.

Prophylactic scopolamine butylbromide reduces death rattle at end of life compared to placebo

Influenza vaccine not associated with increased risk of epilepsy in children

Vaccine-induced immune thrombotic thrombocytopenia may worsen the severity of cerebral venous thrombosis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.